Mimecast Limited (MIME) Forms $38.38 Double Top; Clovis Oncology (CLVS) SI Increased By 1.04%

Mimecast Limited (NASDAQ:MIME) Logo

Mimecast Limited (MIME) formed double top with $41.83 target or 9.00% above today’s $38.38 share price. Mimecast Limited (MIME) has $2.22B valuation. The stock increased 2.13% or $0.8 during the last trading session, reaching $38.38. About 174,067 shares traded. Mimecast Limited (NASDAQ:MIME) has risen 63.99% since April 27, 2017 and is uptrending. It has outperformed by 52.44% the S&P500.

Clovis Oncology Inc (NASDAQ:CLVS) had an increase of 1.04% in short interest. CLVS’s SI was 7.53 million shares in April as released by FINRA. Its up 1.04% from 7.45 million shares previously. With 874,200 avg volume, 9 days are for Clovis Oncology Inc (NASDAQ:CLVS)’s short sellers to cover CLVS’s short positions. The SI to Clovis Oncology Inc’s float is 17.03%. The stock increased 0.44% or $0.2 during the last trading session, reaching $45.3. About 968,113 shares traded. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 21.43% since April 27, 2017 and is downtrending. It has underperformed by 32.98% the S&P500.

Since December 15, 2017, it had 0 insider purchases, and 7 sales for $1.64 million activity. SPICKSCHEN THORLEF had sold 4,500 shares worth $270,090 on Monday, April 9. Another trade for 3,000 shares valued at $162,270 was sold by IVERS-READ GILLIAN C.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has market cap of $2.39 billion. The Company’s commercial product includes Rubraca tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. It currently has negative earnings. The firm is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications.

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 16 have Buy rating, 0 Sell and 4 Hold. Therefore 80% are positive. Clovis Oncology had 64 analyst reports since September 10, 2015 according to SRatingsIntel. As per Friday, March 23, the company rating was maintained by RBC Capital Markets. The rating was downgraded by Goldman Sachs to “Neutral” on Tuesday, November 17. The stock has “Overweight” rating by Morgan Stanley on Thursday, November 2. The rating was maintained by J.P. Morgan with “Buy” on Wednesday, September 6. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, September 21 report. The firm has “Buy” rating given on Monday, February 5 by Leerink Swann. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) earned “Buy” rating by Bank of America on Friday, January 27. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) earned “Neutral” rating by Chardan Capital Markets on Monday, June 19. Mizuho downgraded Clovis Oncology, Inc. (NASDAQ:CLVS) on Monday, November 16 to “Neutral” rating. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) earned “Buy” rating by Suntrust Robinson on Wednesday, August 24.

Investors sentiment decreased to 1.05 in Q4 2017. Its down 0.39, from 1.44 in 2017Q3. It fall, as 35 investors sold Clovis Oncology, Inc. shares while 69 reduced holdings. 31 funds opened positions while 78 raised stakes. 49.09 million shares or 3.43% more from 47.46 million shares in 2017Q3 were reported. Weiss Multi has 0.04% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 25,000 shares. Trust Department Mb National Bank N A accumulated 0% or 235 shares. Los Angeles Cap Management & Equity Research Inc invested in 21,339 shares or 0.01% of the stock. Palo Alto Invsts Ltd Liability accumulated 3.40 million shares or 9.97% of the stock. 182,600 are held by Sectoral Asset Mngmt. Point72 Asset Mngmt L P owns 876,000 shares for 0.26% of their portfolio. Brown Brothers Harriman & has 0% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 63 shares. California State Teachers Retirement System invested 0.01% in Clovis Oncology, Inc. (NASDAQ:CLVS). Millennium Mgmt Ltd Llc has invested 0.02% in Clovis Oncology, Inc. (NASDAQ:CLVS). State Of New Jersey Common Pension Fund D holds 40,000 shares. Carmignac Gestion stated it has 1.32 million shares. 399,734 were accumulated by Pictet Asset Mgmt Limited. Citadel Ltd Liability Corp has 0.01% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 126,803 shares. Price T Rowe Associates Md stated it has 883,977 shares. Bb&T Secs Ltd Limited Liability Company holds 4,025 shares or 0% of its portfolio.

Analysts await Mimecast Limited (NASDAQ:MIME) to report earnings on May, 8. They expect $-0.07 earnings per share, down 40.00% or $0.02 from last year’s $-0.05 per share. After $-0.05 actual earnings per share reported by Mimecast Limited for the previous quarter, Wall Street now forecasts 40.00% negative EPS growth.

Among 9 analysts covering Mimecast (NASDAQ:MIME), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Mimecast has $28 highest and $12 lowest target. $19.08’s average target is -50.29% below currents $38.38 stock price. Mimecast had 11 analyst reports since December 14, 2015 according to SRatingsIntel. The stock has “Overweight” rating by JP Morgan on Friday, October 14. The firm has “Buy” rating given on Wednesday, January 25 by Brean Capital. The firm has “Buy” rating by Dougherty & Company given on Friday, February 10. Northland Capital initiated Mimecast Limited (NASDAQ:MIME) on Tuesday, January 17 with “Outperform” rating. The rating was initiated by Goldman Sachs with “Buy” on Monday, December 14. Barclays Capital initiated Mimecast Limited (NASDAQ:MIME) on Monday, December 14 with “Overweight” rating. RBC Capital Markets initiated it with “Outperform” rating and $15 target in Monday, December 14 report. Jefferies initiated Mimecast Limited (NASDAQ:MIME) rating on Monday, December 14. Jefferies has “Buy” rating and $18 target. On Friday, November 4 the stock rating was maintained by Dougherty & Company with “Buy”. The stock of Mimecast Limited (NASDAQ:MIME) earned “Outperform” rating by Oppenheimer on Monday, December 14.

Clovis Oncology, Inc. (NASDAQ:CLVS) Institutional Positions Chart